(Q35859217)

10 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

The treatment of rheumatoid arthritis. (English)

1 reference

10 August 2017

1 reference

Lee S Simon

1

1 reference

10 August 2017

publication date

1 August 2004

1 reference

Best Practice & Research: Clinical Rheumatology

10 August 2017

published in

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

507-538

1 reference

Efficacy of low-dose methotrexate in rheumatoid arthritis

10 August 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Epidemiology of rheumatic diseases

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Methotrexate use in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Rheumatoid arthritis and cancer risk

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Methotrexate in refractory rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulfasalazine. Adverse effects and desensitization

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Gold salts in the treatment of rheumatoid arthritis. A double-blind study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulphasalazine in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

What happens to patients with rheumatoid arthritis? The long-term outcome of treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Interleukin-11: a new cytokine critical for osteoclast development

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Epidemiology of rheumatoid arthritis: update

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Survival in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Salazopyrin in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The epidemiology of drug treatment failure in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Anti-cytokine therapy for rheumatoid arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Infections and anti–tumor necrosis factor α therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Salazopyrin in the Treatment of Rheumatoid Arthritis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1016/J.BERH.2004.04.005

Identifiers

DOI

10.1016/J.BERH.2004.04.005

1 reference

10 August 2017

1 reference